This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stryker (SYK) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SYK Stock Falls Despite Q2 Earnings & Sales Beat, '25 View Up
by Zacks Equity Research
SYK's second-quarter results reflect strong segmental performance, along with a rise in operating margin.
Stryker (SYK) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of +2.29% and +1.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
GE HealthCare Technologies (GEHC) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
GE HealthCare (GEHC) delivered earnings and revenue surprises of +16.48% and +0.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Will SYK's Q2 Earnings Reflect Strong Growth Despite Tariff Overhang?
by Zacks Equity Research
Stryker's second-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs and tariffs are likely to have continued to hurt margins.
SNN or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SNN vs. SYK: Which Stock Is the Better Value Option?
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ISRG vs. SYK: Which Robotic Surgery Stock Is the Stronger Buy Today?
by Indrajit Bandyopadhyay
Both are leaders in robotic-assisted surgery - Intuitive Surgical in soft tissue procedures and Stryker in orthopedic surgeries. Which company is a better bet now?
Hospital Capex Headwind: Temporary Setback or Lasting Risk for ISRG?
by Indrajit Bandyopadhyay
Intuitive Surgical's global da Vinci growth faces resistance as hospital CapEx tightens abroad, testing leasing and utilization strategies.
Smart Money Going in Senior Health: Key Stocks in Elderly Care
by Urmimala Biswas
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
ISRG Expands Installed Base, But Is Utilization Keeping Pace?
by Indrajit Bandyopadhyay
Intuitive Surgical's installed base tops 10,000, but flat utilization growth raises questions about ROI and system productivity.
HLN vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
HLN vs. SYK: Which Stock Is the Better Value Option?
Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?
by Kinjel Shah
JNJ's MedTech unit eyes second-half growth despite China headwinds, U.S. competition and tariff pressure.
ISRG da Vinci 5 Gets European Nod: Will it Boost the Stock's Prospect?
by Indrajit Bandyopadhyay
ISRG's da Vinci 5 wins CE mark, unlocking Europe's surgical robotics market as U.S. adoption shows strong early traction.
SYK Boosts Foot & Ankle Portfolio With FDA-Cleared Total Ankle System
by Zacks Equity Research
Stryker expands its Foot & Ankle portfolio with FDA-cleared InCompass, targeting streamlined total ankle replacement.
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
by Kinjel Shah
JNJ's MedTech sales face pressure from China and competition but new products may lead to a stronger second half of 2025.
Is ISRG's Procedure Growth Enough to Offset Margin Pressures in 2025?
by Indrajit Bandyopadhyay
Intuitive Surgical raises 2025 procedure outlook after strong Q1 growth, but rising costs and tariff pressure weigh on margins.
BSX Raises 2025 Financial Outlook: What's Backing It?
by Sridatri Sarkar
Boston Scientific lifts its 2025 sales and EPS outlook after a strong Q1, with cardiology and EP segments fueling major gains.
BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?
by Sridatri Sarkar
Boston Scientific's Q1 2025 Endoscopy sales jump 6%, powered by innovation in stents, clips and surgical tools for GI care.
The Zacks Analyst Blog Highlights Mastercard, Verizon Communications, Stryker, Espey Mfg. & Electronics and Comstock Holding
by Zacks Equity Research
MA, VZ, SYK, ESP, and CHCI show strength across sectors, with solid growth, tech advances, and strategic positioning in 2025.
Top Analyst Reports for Mastercard, Verizon & Stryker
by Mark Vickery
MA, VZ, and SYK stand out in today's top analyst picks, fueled by strong growth drivers but tempered by key risks.
Intuitive Surgical's da Vinci 5: Gaining Precision, Power and Potential
by Indrajit Bandyopadhyay
ISRG's da Vinci 5 is gaining momentum with key innovations like Force Feedback and strong Q1 placements boosting adoption.
Why Is Zimmer (ZBH) Down 0.5% Since Last Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PBH vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System
by Zacks Equity Research
Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.